

Tumor Targeting Liposomal Formulation of Cathepsin B-specific Doxorubicin Prodrug for Drug Resistant Cancer Treatment

Ewha Womans University



ONCOLOGY	Lead
Product Type	Liposomal formulation of doxorubicin prodrug (Aposome)
Indication	Colon, Breast and Pancreatic cancer (especially drug-resistant phenotype)
Target	Cancer biomarker (Cathepsin B)
MoA(Mechanism of Action)	<ol style="list-style-type: none"> 1. Tumor accumulation of liposomal formulation via EPR effect 2. Doxorubicin and SMAC (Drug resistance inhibitor) are released from the liposomes by cathepsin B-mediated enzymatic cleavage 3. Doxorubicin and SMAC synergistically eradicate the cancers with drug-resistant phenotype
Competitiveness	First in class - Liposomal formulation for drug-resistant cancer treatment Best in class - Liposomal formulation encapsulating prodrugs
Development Stage	Lead
Route of Administration	Intravenous injection (I.V.)